)
VistaGen Therapeutics (VTGN) investor relations material
VistaGen Therapeutics Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Annual Meeting scheduled for September 10, 2026, to be held virtually at 9:00 am PDT.
Proxy materials and annual report are available online, with options for electronic or paper delivery.
Shareholders are encouraged to review all proxy materials before voting and can vote online.
Voting matters and shareholder proposals
Election of four director nominees: Jon S. Saxe, Ann M. Cunningham, Shawn K. Singh, and Douglas J. Williamson.
Advisory vote to approve compensation of named executive officers.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending March 31, 2027.
Consideration of any other matters that may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting FOR all director nominees and FOR the executive compensation and auditor ratification proposals.
- Board seeks approval for director elections, executive pay, and auditor ratification, emphasizing governance and ESG.VTGN
Proxy filing - Late-stage intranasal drugs show rapid, safe effects for anxiety, depression, and hot flashes.VTGN
TD Cowen 45th Annual Health Care Conference - Pivotal trials for novel neurocircuitry therapies advance, with key data expected next year.VTGN
Stifel 2024 Healthcare Conference - Fasedienol missed primary endpoints in Phase 3 but showed promise in severe social anxiety subgroup.VTGN
Study update - Advanced clinical milestones and maintained cash runway despite increased net loss.VTGN
Q4 2026 - Fasedienol nears pivotal phase III data in SAD, with pipeline progress and cash runway into 2027.VTGN
RBC Capital Markets Global Healthcare Conference 2026 - Net loss rose as R&D spending increased for late-stage trials; cash runway exceeds 12 months.VTGN
Q2 2025 - Net loss rose to $10.7M as R&D spending increased; $108.4M in cash supports ongoing trials.VTGN
Q1 2025 - Phase 3 SAD trials advance, net loss widens, R&D up, cash at $88.6M supports pipeline.VTGN
Q3 2025
Next VistaGen Therapeutics earnings date
Next VistaGen Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)